MannKind Corporation (MNKD) Receiving Somewhat Positive Press Coverage, Report Finds

Media stories about MannKind Corporation (NASDAQ:MNKD) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MannKind Corporation earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.7747610790628 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of MannKind Corporation (MNKD) opened at $3.26 on Friday. MannKind Corporation has a one year low of $0.67 and a one year high of $6.96. The company has a current ratio of 0.31, a quick ratio of 0.28 and a debt-to-equity ratio of -0.43.

MannKind Corporation (NASDAQ:MNKD) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.56 million. MannKind Corporation had a negative net margin of 155.83% and a negative return on equity of 24.93%. The firm’s revenue for the quarter was down 98.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.30 earnings per share. equities analysts forecast that MannKind Corporation will post -1.13 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research cut shares of MannKind Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. HC Wainwright reaffirmed a “buy” rating on shares of MannKind Corporation in a research note on Wednesday, November 8th. ValuEngine lowered shares of MannKind Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Maxim Group reaffirmed a “hold” rating on shares of MannKind Corporation in a research note on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. MannKind Corporation presently has a consensus rating of “Hold” and an average price target of $0.92.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at

In related news, Director Kent Kresa bought 166,600 shares of the stock in a transaction dated Friday, October 13th. The stock was purchased at an average cost of $6.00 per share, with a total value of $999,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is currently owned by insiders.

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind Corporation (NASDAQ:MNKD)

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply